Sorafenib

For research use only. Not for use in humans.

目录号：S7397 别名： BAY 43-9006

Molecular Weight(MW): 464.82

Sorafenib是Raf-1, B-Raf和VEGFR-2的多重激酶抑制剂，无细胞试验中IC50分别为6 nM, 22 nM和90 nM。

规格

价格

库存

购买数量

20mg	RMB 1205.41	现货
50mg	RMB 2214.52	现货
200mg	RMB 5503.41	现货
大包装	有超大折扣

大剂量询单有大折扣！

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck生产的Sorafenib发表文献206篇：

Cell, 2019, 178(6):1478-1492

PubMed: 31474362 ( click the link to review the publication )

Cancer Discov, 2019, 9(1):46-63

PubMed: 30266815 ( click the link to review the publication )

Gastroenterology, 2017, 152(5):1161-1173

PubMed: 27956228 ( click the link to review the publication )

Cancer Discov, 2015, 10.1158/2159-8290.CD-15-0913

PubMed: 26566875 ( click the link to review the publication )

Nat Chem Biol, 2012, 8(11):905-912

PubMed: 23023260 ( click the link to review the publication )

Int J Oncol, 2020, 56(2):439-447

PubMed: 31894265 ( click the link to review the publication )

Sci Transl Med, 2019, 11(492)

PubMed: 31092693 ( click the link to review the publication )

Mol Cell, 2019, 75(4):669-682

PubMed: 31302002 ( click the link to review the publication )

Nat Commun, 2019, 10(1):5755

PubMed: 31848340 ( click the link to review the publication )

Nat Commun, 2019, 10(1):3051

PubMed: 31296864 ( click the link to review the publication )

Theranostics, 2019, 9(13):3768-3779

PubMed: 31281512 ( click the link to review the publication )

Cell Rep, 2019, 29(3):573-588

PubMed: 31618628 ( click the link to review the publication )

Cell Death Differ, 2019, 10.1038/s41418-019-0399-1

PubMed: 31367013 ( click the link to review the publication )

Cell Death Differ, 2019, 10.1038/s41418-019-0338-1

PubMed: 31065106 ( click the link to review the publication )

Int J Cancer, 2019, 10.1002/ijc.32543

PubMed: 31259424 ( click the link to review the publication )

Cancer Lett, 2019, 466:23-34

PubMed: 31521695 ( click the link to review the publication )

Cancer Lett, 2019, 460:96-107

PubMed: 31247273 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):83

PubMed: 30770740 ( click the link to review the publication )

Cancers (Basel), 2019, 11(9)

PubMed: 31547367 ( click the link to review the publication )

Cancers (Basel), 2019, 11(3)

PubMed: 30901922 ( click the link to review the publication )

Cancers (Basel), 2019, 11(4)

PubMed: 31018508 ( click the link to review the publication )

Cell Death Dis, 2019, 10(10):784

PubMed: 31611551 ( click the link to review the publication )

Cell Death Discov, 2019, 5:86

PubMed: 30962952 ( click the link to review the publication )

Cell Death Dis, 2019, 10(10):682

PubMed: 31527591 ( click the link to review the publication )
Br J Cancer, 2019, 120(5):512-521

PubMed: 30765873 ( click the link to review the publication )

Br J Cancer, 2019, 121(7):567-577

PubMed: 31474759 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(3):718-725

PubMed: 30755456 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(11):2146-2157

PubMed: 31439713 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(5):947-956

PubMed: 30926637 ( click the link to review the publication )

Cell Commun Signal, 2019, 17(1):85

PubMed: 31349793 ( click the link to review the publication )

Neoplasia, 2019, 22(1):1-9

PubMed: 31751859 ( click the link to review the publication )

Neoplasia, 2019, 21(3):257-268

PubMed: 30685691 ( click the link to review the publication )

Pharmacol Res, 2019, 143:73-85

PubMed: 30862605 ( click the link to review the publication )

Eur J Med Chem, 2019, 168:315-329

PubMed: 30826508 ( click the link to review the publication )

Cell Oncol (Dordr), 2019, 10.1007/s13402-019-00458-8

PubMed: 31250364 ( click the link to review the publication )

Mol Cancer Res, 2019, 10.1158/1541-7786.MCR-18-1332

PubMed: 31043489 ( click the link to review the publication )

J Cell Physiol, 2019, 234(3):2639-2648

PubMed: 30145835 ( click the link to review the publication )

J Cell Mol Med, 2019, 23(11):7349-7359

PubMed: 31507082 ( click the link to review the publication )

J Steroid Biochem Mol Biol, 2019, 197:105524

PubMed: 31704246 ( click the link to review the publication )

Am J Physiol Lung Cell Mol Physiol, 2019, 316(2-:L348-L357

PubMed: 30489156 ( click the link to review the publication )

Am J Physiol Gastrointest Liver Physiol, 2019, 316(1-:G15-G24

PubMed: 30406699 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2019, 379:114665

PubMed: 31323261 ( click the link to review the publication )

J Cell Biochem, 2019, 120(1):928-939

PubMed: 30160785 ( click the link to review the publication )

Ann Biomed Eng, 2019, 10.1007/s10439-019-02269-2

PubMed: 31020445 ( click the link to review the publication )

Exp Gerontol, 2019, 126:110691

PubMed: 31421186 ( click the link to review the publication )

Transl Oncol, 2019, 12(7):917-924

PubMed: 31082584 ( click the link to review the publication )

Oncol Rep, 2019, 41(6):3257-3269

PubMed: 31002342 ( click the link to review the publication )

Oncol Rep, 2019, 41(3):2041-2050

PubMed: 30569112 ( click the link to review the publication )
Biosci Rep, 2019, 39(4)

PubMed: 30914455 ( click the link to review the publication )

Biochem Biophys Res Commun, 2019, 510(2):278-283

PubMed: 30686534 ( click the link to review the publication )

Onco Targets Ther, 2019, 12:1629-1640

PubMed: 30881018 ( click the link to review the publication )

Artif Cells Nanomed Biotechnol, 2019, 47(1):83-89

PubMed: 30663411 ( click the link to review the publication )

Assay Drug Dev Technol, 2019, 17(3):100-115

PubMed: 30958702 ( click the link to review the publication )

Nat Commun, 2018, 9(1):4821

PubMed: 30446652 ( click the link to review the publication )

EMBO Mol Med, 2018, 10(9)

PubMed: 30108112 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(2):474-485

PubMed: 29084919 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(5):1090-1102

PubMed: 29196297 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(16):3941-3954

PubMed: 29764852 ( click the link to review the publication )

Small, 2018, 14(47):e1802372

PubMed: 30307695 ( click the link to review the publication )

Cancer Res, 2018, 78(16):4704-4715

PubMed: 29895675 ( click the link to review the publication )

Haematologica, 2018, 103(10):1642-1653

PubMed: 29773601 ( click the link to review the publication )

EMBO Rep, 2018, 19(2):320-336

PubMed: 29263201 ( click the link to review the publication )

Cancer Lett, 2018, 420:49-59

PubMed: 29409989 ( click the link to review the publication )

Breast Cancer Res, 2018, 20(1):9

PubMed: 29382358 ( click the link to review the publication )

Cell Death Dis, 2018, 9(7):743

PubMed: 29970890 ( click the link to review the publication )

Br J Cancer, 2018, 119(4):450-461

PubMed: 30033448 ( click the link to review the publication )

Cell Death Dis, 2018, 9(6):646

PubMed: 29844385 ( click the link to review the publication )

Cell Death Dis, 2018, 9(10):935

PubMed: 30224718 ( click the link to review the publication )

Cell Chem Biol, 2018, 25(2):175-184

PubMed: 29249695 ( click the link to review the publication )

Bioinformatics, 2018, 34(23):4079-4086

PubMed: 29931053 ( click the link to review the publication )

Pharmacol Res, 2018, 135:188-200

PubMed: 30114438 ( click the link to review the publication )

Cancer Sci, 2018, 109(4):1207-1219

PubMed: 29446853 ( click the link to review the publication )
Int J Nanomedicine, 2018, 13:8339-8354

PubMed: 30584304 ( click the link to review the publication )

Lab Invest, 2018, 98(12):1600-1613

PubMed: 30206312 ( click the link to review the publication )

Front Pharmacol, 2018, 9:194

PubMed: 29563873 ( click the link to review the publication )

Front Pharmacol, 2018, 9:432

PubMed: 29760660 ( click the link to review the publication )

Cancer Manag Res, 2018, 10:3057-3067

PubMed: 30214300 ( click the link to review the publication )

Int J Oncol, 2018, 52(6):2051-2060

PubMed: 29620259 ( click the link to review the publication )

Acta Pharmacol Sin, 2018, 39(3):438-448

PubMed: 29188798 ( click the link to review the publication )

Cancer Biol Ther, 2018, 19(11):1057-1064

PubMed: 30277836 ( click the link to review the publication )

Exp Cell Res, 2018, 369(1):69-79

PubMed: 29752949 ( click the link to review the publication )

BMC Cancer, 2018, 18(1):542

PubMed: 29739364 ( click the link to review the publication )

J Cancer Res Clin Oncol, 2018, 144(8):1487-1501

PubMed: 29858683 ( click the link to review the publication )

Transl Oncol, 2018, 11(6):1406-1418

PubMed: 30219696 ( click the link to review the publication )

Oncol Rep, 2018, 40(6):3235-3248

PubMed: 30272354 ( click the link to review the publication )

Biochem Biophys Res Commun, 2018, 504(4):878-884

PubMed: 30219235 ( click the link to review the publication )

Onco Targets Ther, 2018, 11:2945-2954

PubMed: 29849464 ( click the link to review the publication )

Onco Targets Ther, 2018, 11:5885-5894

PubMed: 30271172 ( click the link to review the publication )

Biochem Biophys Res Commun, 2018, 502(1):110-115

PubMed: 29787755 ( click the link to review the publication )

Exp Hematol, 2018, 67:49-59

PubMed: 30102945 ( click the link to review the publication )

Mol Med Rep, 2018, 17(6):8101-8110

PubMed: 29693132 ( click the link to review the publication )

Mol Med Rep, 2018, 17(6):8053-8060

PubMed: 29693700 ( click the link to review the publication )

Oncotarget, 2018, 9(56):30869-30882

PubMed: 30112114 ( click the link to review the publication )

Oncotarget, 2018, 9(51):29680-29697

PubMed: 30038713 ( click the link to review the publication )

Biochim Biophys Acta Gen Subj, 2018, 1862(4):1017-1030

PubMed: 29369785 ( click the link to review the publication )

Curr Biol, 2018, 28(15):2388-2399

PubMed: 30057310 ( click the link to review the publication )
Autophagy, 2018, 14(12):2083-2103

PubMed: 30081711 ( click the link to review the publication )

J Clin Invest, 2017, 127(1):153-168

PubMed: 27893461 ( click the link to review the publication )

Nat Commun, 2017, 8:15090

PubMed: 28489072 ( click the link to review the publication )

Oncogene, 2017, 36(48):6691-6700

PubMed: 28745317 ( click the link to review the publication )

Cancer Lett, 2017, 406:105-115

PubMed: 28687354 ( click the link to review the publication )

J Med Chem, 2017, 61(1):140-157

PubMed: 29189002 ( click the link to review the publication )

J Exp Clin Cancer Res, 2017, 36(1):8

PubMed: 28069043 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(10-:2130-2143

PubMed: 28751539 ( click the link to review the publication )

J Am Heart Assoc, 2017, 6(10)

PubMed: 29051215 ( click the link to review the publication )

Front Cell Neurosci, 2017, 11:303

PubMed: 29033791 ( click the link to review the publication )

Sci Rep, 2017, 7(1):13832

PubMed: 29062139 ( click the link to review the publication )

Acta Pharmacol Sin, 2017, 38(11):1533-1542

PubMed: 28795691 ( click the link to review the publication )

Methods, 2017, 130:63-71

PubMed: 28916148 ( click the link to review the publication )

Int J Oncol, 2017, 50(1):297-309

PubMed: 27959383 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 491(4):919-925

PubMed: 28756230 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 489(1):14-20

PubMed: 28536078 ( click the link to review the publication )

Oncotarget, 2017, 8(5):8035-8042

PubMed: 28030831 ( click the link to review the publication )

Oncotarget, 2017, 9(4):5111-5124

PubMed: 29435166 ( click the link to review the publication )

Hepatology, 2016, 64(2):488-500

PubMed: 27015352 ( click the link to review the publication )

Hepatology, 2016, 64(5):1637-1651

PubMed: 27530187 ( click the link to review the publication )

ACS Nano, 2016, 10(11):9999-10012

PubMed: 27934069 ( click the link to review the publication )

Genome Biol, 2016, 17:80

PubMed: 27139883 ( click the link to review the publication )

Nat Commun, 2016, 7:11363

PubMed: 27193833 ( click the link to review the publication )

Clin Cancer Res, 2016, 22(8):1940-50

PubMed: 26578684 ( click the link to review the publication )
Clin Cancer Res, 2016, 22(7):1687-98

PubMed: 26603259 ( click the link to review the publication )

Leukemia, 2016, 30(4):937-46

PubMed: 26582644 ( click the link to review the publication )

Cancer Immunol Res, 2016, 4(7):574-81

PubMed: 27197065 ( click the link to review the publication )

Cancer Res, 2016, 76(6):1528-37

PubMed: 26822154 ( click the link to review the publication )

J Exp Clin Cancer Res, 2016, 35(1):159

PubMed: 27716356 ( click the link to review the publication )

Mol Oncol, 2016, 10(1):101-12

PubMed: 26471831 ( click the link to review the publication )

Am J Physiol Lung Cell Mol Physiol, 2016, 310(2-:L187-201

PubMed: 26589479 ( click the link to review the publication )

Biochem Biophys Res Commun, 2016, pii: S0006-291X(16)30677-5

PubMed: 27144317 ( click the link to review the publication )

J Surg Res, 2016, 206(2):371-379

PubMed: 27884331 ( click the link to review the publication )

Tumour Biol, 2016, 37(6):8047-55

PubMed: 26711788 ( click the link to review the publication )

Tumour Biol, 2016, 37(5):6987-96

PubMed: 26662956 ( click the link to review the publication )

Oncotarget, 2016, 7(18-:25983-6002

PubMed: 27036020 ( click the link to review the publication )

Nat Commun, 2015, 6:6240

PubMed: 25670642 ( click the link to review the publication )

Sci Adv, 2015, 1(8):e1500221

PubMed: 26601252 ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(10-:2238-48

PubMed: 26208525 ( click the link to review the publication )

Eur J Med Chem, 2015, 93:523-38

PubMed: 25743214 ( click the link to review the publication )

Antimicrob Agents Chemother, 2015, 59(2):1088-99

PubMed: 25487801 ( click the link to review the publication )

J Cell Physiol, 2015, 10.1002/jcp.24961

PubMed: 25704960 ( click the link to review the publication )

J Cell Physiol, 2015, 230(9):2281-98

PubMed: 25704960 ( click the link to review the publication )

Exp Cell Res, 2015, 331(1):97-104

PubMed: 25447203 ( click the link to review the publication )

Biochem Biophys Res Commun, 2015, 10.1016/j.bbrc.2015.02.084

PubMed: 25712526 ( click the link to review the publication )

Anticancer Res, 2015, 35(3):1803-8

PubMed: 25750346 ( click the link to review the publication )

Clin Mol Hepatol, 2015, 21(1):49-59

PubMed: 25834802 ( click the link to review the publication )

Gut, 2014, 63(4):674-85

PubMed: 23958557 ( click the link to review the publication )
Nat Commun, 2014, 5:3901

PubMed: 24849047 ( click the link to review the publication )

Nat Commun, 2014, 5:5637

PubMed: 25472497 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(23):6034-44

PubMed: 25294906 ( click the link to review the publication )

Elife, 2014, 3:e02523

PubMed: 24844246 ( click the link to review the publication )

Sci Signal, 2014, 7(322):ra38

PubMed: 24757178 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1223

PubMed: 24810059 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1278

PubMed: 24901049 ( click the link to review the publication )

Mol Oncol, 2014, 8(7):1339-54

PubMed: 24908424 ( click the link to review the publication )

Mol Oncol, 2014, 8(7):1339-54

PubMed: 24908424 ( click the link to review the publication )

Stem Cell Res Ther, 2014, 5(2):37

PubMed: 24635859 ( click the link to review the publication )

Stem Cell Res Ther, 2014, 5(2):37

PubMed: 24635859 ( click the link to review the publication )

Mol Cancer Res, 2014, 10.1158/1541-7786.MCR-13-0636

PubMed: 24874432 ( click the link to review the publication )

Mol Cancer Res, 2014, 12(10):1377-87

PubMed: 24874432 ( click the link to review the publication )

J Cell Sci, 2014, 127(Pt 7):1585-94

PubMed: 24463816 ( click the link to review the publication )

J Cell Sci, 2014, 127(Pt 7):1585-94

PubMed: 24463816 ( click the link to review the publication )

Apoptosis, 2014, 19(4):682-97

PubMed: 24337903 ( click the link to review the publication )

Apoptosis, 2014, 19(4):682-97

PubMed: 24337903 ( click the link to review the publication )

J Proteomics, 2014, 113:326-36

PubMed: 25451013 ( click the link to review the publication )

Drug Metab Dispos, 2014, 42(3):318-22

PubMed: 24335466 ( click the link to review the publication )

Biol Blood Marrow Transplant, 2014, 20(11):1687-95

PubMed: 25111583 ( click the link to review the publication )

Int J Oncol, 2014, 45(5):2167-75

PubMed: 25175082 ( click the link to review the publication )

Oncol Rep, 2014, 31(6):2611-8

PubMed: 24788596 ( click the link to review the publication )

Oncol Rep, 2014, 32(6):2421-8

PubMed: 25242034 ( click the link to review the publication )

PLoS One, 2014, 9(6):e100814

PubMed: 24956259 ( click the link to review the publication )
PLoS One, 2014, 9(2):e88587

PubMed: 24523919 ( click the link to review the publication )

PLoS One, 2014, 9(6):e97739

PubMed: 24905462 ( click the link to review the publication )

PLoS One, 2014, 9(6):e100814

PubMed: 24956259 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 10.1016/j.bbrc.2014.05.057

PubMed: 24858691 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 450(1):19-24

PubMed: 24858691 ( click the link to review the publication )

Blood Cells Mol Dis, 2014, 52(4):214-24

PubMed: 24314748 ( click the link to review the publication )

FEBS Open Bio, 2014, 4:458-67

PubMed: 24918061 ( click the link to review the publication )

FEBS Open Bio, 2014, 4:458-67

PubMed: 24918061 ( click the link to review the publication )

Blood, 2013, 122(9):1621-33

PubMed: 23863897 ( click the link to review the publication )

Hepatology, 2013, 59(4):1435-47

PubMed: 24242874 ( click the link to review the publication )

Nat Chem Biol, 2013, 9(5):307-12

PubMed: 23502424 ( click the link to review the publication )

J Neurosci, 2013, 33(7):3079-93

PubMed: 23407963 ( click the link to review the publication )

Br J Cancer, 2013, 109(3):686-93

PubMed: 23839492 ( click the link to review the publication )

Lab Invest, 2013, 93(1):8-19

PubMed: 23108376 ( click the link to review the publication )

Mol Pharmacol, 2013, 84(4):562-71

PubMed: 23877009 ( click the link to review the publication )

Drug Metab Dispos, 2013, 10.1124/dmd.113.054189

PubMed: 24335466 ( click the link to review the publication )

Mol Cell Endocrinol, 2013, 377(1-2):1-6

PubMed: 23811235 ( click the link to review the publication )

PLoS One, 2013, 8(1):e54595

PubMed: 23355882 ( click the link to review the publication )

PLoS One, 2013, 8(12):e83521

PubMed: 24376712 ( click the link to review the publication )

Mol Cell Biochem, 2013, 372(1-2):65-74

PubMed: 22941213 ( click the link to review the publication )

J Biomol Screen, 2013, 19(4):526-37

PubMed: 24361645 ( click the link to review the publication )

Blood Cells Mol Dis, 2013, 52(4):214-24

PubMed: 24314748 ( click the link to review the publication )

Sci Transl Med, 2012, 4(136):136ra70

PubMed: 22649091 ( click the link to review the publication )

Blood, 2012, 120(19):4104-15

PubMed: 23007403 ( click the link to review the publication )
Haematologica, 2012, 97(11):1722-30

PubMed: 22689683 ( click the link to review the publication )

Cell Death Differ, 2012, 19(12):2029-39

PubMed: 22858545 ( click the link to review the publication )

Int J Cancer, 2012, 131(12):2961-9

PubMed: 22514082 ( click the link to review the publication )

Br J Haematol, 2012, 157(4):510-4

PubMed: 22313359 ( click the link to review the publication )

Br J Haematol, 2012, 157(4):483-92

PubMed: 22409268 ( click the link to review the publication )

Mol Pharm, 2012, 9(11):3062-78

PubMed: 22971013 ( click the link to review the publication )

Biochem Pharmacol, 2012, 83(12):1674-81

PubMed: 22414727 ( click the link to review the publication )

J Proteomics, 2012, 79:114-22

PubMed: 23268119 ( click the link to review the publication )

Surgery, 2012, 152(6):1142-9

PubMed: 23158184 ( click the link to review the publication )

Invest New Drugs, 2012, 31(3):780-6

PubMed: 23154882 ( click the link to review the publication )

Clin Cancer Res, 2011, 17(24):7595-604

PubMed: 22038996 ( click the link to review the publication )

J Invest Dermatol, 2011, 131(9):1886-95

PubMed: 21654832 ( click the link to review the publication )

Mol Pharmacol, 2011, 80(6):1066-75

PubMed: 21896713 ( click the link to review the publication )

Int J Parasitol, 2010, 40(5):555-67

PubMed: 19887070 ( click the link to review the publication )

产品安全说明书

Raf抑制剂选择性比较

生物活性

产品描述

Sorafenib是Raf-1, B-Raf和VEGFR-2的多重激酶抑制剂，无细胞试验中IC50分别为6 nM, 22 nM和90 nM。

靶点

Raf-1 ^[1] (Cell-free assay)	mVEGFR2(Flk1) ^[1] (Cell-free assay)	mVEGFR3 ^[1] (Cell-free assay)	B-Raf ^[1] (Cell-free assay)	B-Raf (V599E) ^[1] (Cell-free assay)	点击更多
6 nM	15 nM	20 nM	22 nM	38 nM	点击更多

体外研究

Sorafenib抑制野生型和V599E突变型B-Raf活性，IC50分别为22 nM 和 38 nM。Sorafenib也能有效抑制mVEGFR2 (Flk-1)，mVEGFR3，mPDGFRβ，Flt3，和c-Kit，IC50分别为15 nM，20 nM，57 nM，58 nM，和68 nM。Sorafenib 能够较弱地抑制FGFR-1，IC50 为580 nM。Sorafenib对ERK-1，MEK-1，EGFR，HER-2，IGFR-1，c-Met，PKB，PKA，cdk1/cyclinB，PKCα，PKCγ，和pim-1没有活性。Sorafenib显著抑制NIH 3T3细胞中VEGFR2磷酸化，IC50 为 30 nM，也会抑制HEK-293细胞中Flt-3磷酸化，IC50 为20 nM。Sorafenib有效阻断大多数细胞中MEK 1/2 和 ERK 1/2磷酸化，但不阻断A549 或 H460细胞中该过程，同时不影响PKB通路的抑制。Sorafenib抑制HAoSMC 和 MDA-MB-231细胞的增殖，IC50分别为0.28 μM 和 2.6 μM。^[1]除了抑制RAF/MEK/ERK信号通路，Sorafenib tosylate显著抑制eIF4E的磷酸化作用，并以MEK/ERK依赖的方式下调肝癌(HCC)细胞中Mcl-1水平。Sorafenib 抑制PLC/PRF/5 和HepG2细胞的增殖，IC50分别为6.3 μM 和 4.5 μM，并诱导显著的细胞凋亡。^[2]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
MV-4-11	NGHBPWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1vDXWlEPTB;MD6wNFAxODNyMzFOwG0>	NWLqSpVvW0GQR1XS
MONO-MAC-6	M{W4PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2jvXmlEPTB;MD6wNFQyQCEQvF2=	NUj5SY1mW0GQR1XS
ALL-PO	NX3sZ5lIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkDKTWM2OD1yLkCzNVg1KM7:TR?=	M2e0fXNCVkeHUh?=
NKM-1	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV7yd21oUUN3ME2wMlA4PDF4IN88US=>	NF3yfJJUSU6JRWK=
CGTH-W-1	MoLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV;xWldZUUN3ME2wMlI2ODJ{IN88US=>	NXvHb2dbW0GQR1XS
BB65-RCC	NGjzTJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEfQXZFKSzVyPUCuOFcxPzNizszN	NEXzZ\|VUSU6JRWK=
NOS-1	M4PsU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUX5RWNJUUN3ME2wMlU3OzZizszN	M2O2enNCVkeHUh?=
SH-4	M4WwN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUfrTYdiUUN3ME2wMlY2PjF\|IN88US=>	NVnYOGdEW0GQR1XS
HOP-62	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEjNeI1KSzVyPUCuPFUxQDhizszN	MUPTRW5ITVJ?
HCC2998	NWDJW4dTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXTJR\|UxRTBwOEi4NVgh\|ryP	MV7TRW5ITVJ?
GDM-1	NGnXUXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoHQTWM2OD1yLkmwOlk5KM7:TR?=	MkLLV2FPT0WU
KM12	M{jpUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGPvb\|RKSzVyPUGuNFIxQThizszN	NX;Tc4IxW0GQR1XS
LB2518-MEL	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVrJR\|UxRTFwMkC4NFkh\|ryP	M375NXNCVkeHUh?=
NCI-H1436	MlvvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4nINmlEPTB;MT6yNVY4QCEQvF2=	NWfHOXhJW0GQR1XS
EM-2	M321Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYDJR\|UxRTFwM{W1O\|gh\|ryP	MX\TRW5ITVJ?
LAMA-84	M3naWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFvNSFRKSzVyPUGuN\|c3PDhizszN	M{T2dXNCVkeHUh?=
KG-1	MnLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2O4fGlEPTB;MT60O\|k{PSEQvF2=	NXfNOWNTW0GQR1XS
A388	Ml7TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1vFU2lEPTB;MT61PVE3PSEQvF2=	MnrVV2FPT0WU
no-10	NIPPW\|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHX0b5hKSzVyPUGuOlE4OjZizszN	NIXieGtUSU6JRWK=
SF126	MkOyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnLlTWM2OD1zLk[zPFEzKM7:TR?=	NV7pOIN2W0GQR1XS
MEG-01	NHfOTGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIXLWnhKSzVyPUGuPFA6QCEQvF2=	NXi0XlZvW0GQR1XS
A3-KAW	M133SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVfJR\|UxRTFwOEi0NkDPxE1?	MVHTRW5ITVJ?
D-247MG	NFPuPW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXTR[Zc1UUN3ME2yMlE1PDhizszN	M4\LWnNCVkeHUh?=
OVCAR-4	NHXZfJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2nId2lEPTB;Mj6yNVM6OyEQvF2=	NVvFZ3hqW0GQR1XS
NCI-SNU-1	NUDYV\|ljT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2e2RmlEPTB;Mj6zNVYzKM7:TR?=	MX3TRW5ITVJ?
NCI-H2171	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWTJR\|UxRTJwM{m3OlQh\|ryP	NX;5eHpEW0GQR1XS
SIG-M5	M2jCOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUXJR\|UxRTJwNEKyOFIh\|ryP	NFTCO2pUSU6JRWK=
BE-13	Mm\sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1TvWmlEPTB;Mj62PVYxQSEQvF2=	NIDDfHlUSU6JRWK=
K052	NGL0NFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWnPUnp6UUN3ME2yMlc1PjF4IN88US=>	NYrIUVVCW0GQR1XS
L-540	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{\qcmlEPTB;Mj63OVc5QSEQvF2=	NV7FOY1rW0GQR1XS
KMOE-2	NVLXRm1pT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFTkOXVKSzVyPUKuPFE{PSEQvF2=	Mm\UV2FPT0WU
MFH-ino	MlGxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnXBTWM2OD1{LkmyNVg2KM7:TR?=	M33kU3NCVkeHUh?=
HL-60	NXL1TGo3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnTTTWM2OD1\|LkC2Nlk6KM7:TR?=	M2C0XXNCVkeHUh?=
HCC2218	NVXVT4VwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2LmeGlEPTB;Mz6xNlAxOyEQvF2=	NYDGbpEzW0GQR1XS
TE-5	NFXFSVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGfiVZNKSzVyPUOuNVMyPjJizszN	MVzTRW5ITVJ?
MZ1-PC	M2jUd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV\Y[3drUUN3ME2zMlQ4PTB7IN88US=>	M2DTbHNCVkeHUh?=
MRK-nu-1	NIX5NINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX;qWJNjUUN3ME2zMlYyPDZ6IN88US=>	NIS3V\|ZUSU6JRWK=
MZ7-mel	M1\Eemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGnENFNKSzVyPUOuOlYxQTlizszN	M2HIO3NCVkeHUh?=
BC-1	Mn3OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MomzTWM2OD1\|Lke0NFIh\|ryP	M2XrbnNCVkeHUh?=
ST486	MnLDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYPJR\|UxRTNwOEO2O\|Mh\|ryP	NV;qeI5kW0GQR1XS
KS-1	MmS2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYDJR\|UxRTNwOEixPVgh\|ryP	Mlj2V2FPT0WU
SK-NEP-1	Ml[0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVnJR\|UxRTRwMU[4NVUh\|ryP	NY[1VoRLW0GQR1XS
BC-3	MkLlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2DCV2lEPTB;ND6yN\|M6OSEQvF2=	MUDTRW5ITVJ?
NCI-H1581	M{PDeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnPGTWM2OD12LkK4O\|k5KM7:TR?=	Mn\JV2FPT0WU
MHH-PREB-1	NXjySGdOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmHXTWM2OD12LkSwOFg1KM7:TR?=	M4e5dXNCVkeHUh?=
NOMO-1	M{D1Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoKzTWM2OD12LkS4PVA2KM7:TR?=	NUn0R3VFW0GQR1XS
QIMR-WIL	NWTmV3h1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3;JbWlEPTB;NT6wO\|I6PCEQvF2=	MYDTRW5ITVJ?
SF539	NFu3U4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWL6dJhqUUN3ME21MlE{OjJ5IN88US=>	MlL3V2FPT0WU
TE-12	MkmxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVjJR\|UxRTVwMkS5Nlkh\|ryP	MkfRV2FPT0WU
NCI-H510A	MmP0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUnJR\|UxRTVwNEG2PFUh\|ryP	M2DNOHNCVkeHUh?=
JAR	NU\IbFhDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXvJR\|UxRTVwNUC4NlQh\|ryP	MVXTRW5ITVJ?
no-11	M4PvUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWPJR\|UxRTVwN{O1Olgh\|ryP	NX;sdXVrW0GQR1XS
BV-173	NV24RY5ZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmPNTWM2OD13Lkm1OlgzKM7:TR?=	M4PRPHNCVkeHUh?=
SR	MoL1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2rTNmlEPTB;Nj6wNFY4QCEQvF2=	M3;aVXNCVkeHUh?=
MOLT-16	MmfCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M36xO2lEPTB;Nj6yOVI3PiEQvF2=	NH7oUVhUSU6JRWK=
MZ2-MEL	Mn3tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkXUTWM2OD14LkOxPFM6KM7:TR?=	NULRSHR1W0GQR1XS
SW954	NE\SRVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2PJc2lEPTB;Nj60OVg3PiEQvF2=	NGS3b4pUSU6JRWK=
ML-2	NWXrbllvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1zXcGlEPTB;Nj61Nlg1QSEQvF2=	NHvmd3NUSU6JRWK=
OCI-AML2	NHHEUGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkSyTWM2OD14Lk[xNFYzKM7:TR?=	MXzTRW5ITVJ?
SIMA	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXeyRXNvUUN3ME23MlAxOTBzIN88US=>	MnezV2FPT0WU
DOHH-2	NFjjSnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1fPW2lEPTB;Nz6wOVY4PiEQvF2=	NFjpdZdUSU6JRWK=
697	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXTJR\|UxRTdwMEW5PFkh\|ryP	NEHOUZRUSU6JRWK=
NB1	M1nsbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3:2XmlEPTB;Nz60NFQxPyEQvF2=	NYfJZodMW0GQR1XS
D-392MG	NHryT2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1H6fGlEPTB;Nz62NlY3OyEQvF2=	NWHiPGRHW0GQR1XS
ES8	NHHz[\|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVLCbZdrUUN3ME23Mlc3PTB\|IN88US=>	MVzTRW5ITVJ?
RPMI-8226	M1n1U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHHWVVZKSzVyPUeuPFQ2OTFizszN	NXizeGRIW0GQR1XS
IST-MEL1	M3n6fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXPjVok1UUN3ME24MlQxODB{IN88US=>	NXXo[ZJOW0GQR1XS
NB14	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYTEfHpjUUN3ME24MlY{OTN\|IN88US=>	M4e1cHNCVkeHUh?=
HD-MY-Z	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVjJR\|UxRThwNkO3OFYh\|ryP	MW\TRW5ITVJ?
TE-10	MnfnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGT4OplKSzVyPUiuO\|Y{PTNizszN	NVflTml1W0GQR1XS
LC-1F	NFXpcY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF2wcmtKSzVyPUmuNVA5OzRizszN	NGX4[XNUSU6JRWK=
OS-RC-2	M3[xVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWDXTWVjUUN3ME25MlEyOjR\|IN88US=>	M2nsUnNCVkeHUh?=
NCI-SNU-16	NYOweYhpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkDaTWM2OD17LkKxNFI3KM7:TR?=	NYK2[JU6W0GQR1XS
SHP-77	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUT5eYhoUUN3ME25MlcyPjZ{IN88US=>	NWDzUVlMW0GQR1XS
A4-Fuk	MmDNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWj0VGFrUUN3ME25Mlc2PjFizszN	M4PRNnNCVkeHUh?=
NB6	M3GzTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXfJR\|UxRTlwN{[wNlkh\|ryP	NUK0eXJ5W0GQR1XS
JiyoyeP-2003	NXPwc2RpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVPJR\|UxRTFyLkS3OFUh\|ryP	NU\lWZhmW0GQR1XS
DMS-114	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmTuTWM2OD1zMD61OFQyKM7:TR?=	NFPmXmZUSU6JRWK=
NB7	NFGzdFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3jNW2lEPTB;MUCuO\|UzPiEQvF2=	NWr0[XNLW0GQR1XS
NCI-H747	NVLaN3pmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH3IS5dKSzVyPUGxMlEzOTZizszN	MWjTRW5ITVJ?
HH	NIfEXXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3WxN2lEPTB;MUGuN\|g4PiEQvF2=	MnzlV2FPT0WU
EW-18	NILhboRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnPBTWM2OD1zMT65NFQ1KM7:TR?=	NH7wV4pUSU6JRWK=
CHP-126	MmTnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVjJR\|UxRTFzLkm3N\|gh\|ryP	MmHUV2FPT0WU
NTERA-S-cl-D1	M1PpNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHrzTIdKSzVyPUGyMlAzPzhizszN	MVHTRW5ITVJ?
DEL	NGj6TFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mm\pTWM2OD1zMj6wPVg2KM7:TR?=	NWrJUIFuW0GQR1XS
LU-139	NVjnWGNVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3;QSGlEPTB;MUKuOVQyOyEQvF2=	M{fYcXNCVkeHUh?=
P30-OHK	M2X1dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3jmXWlEPTB;MUKuOVQ4QSEQvF2=	M2L4eHNCVkeHUh?=
NCI-H1522	NXX4U3FVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnnYTWM2OD1zMj63OFYh\|ryP	MVTTRW5ITVJ?
NCI-H1299	NGm0c4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVnJR\|UxRTF\|LkK5NVEh\|ryP	MmTVV2FPT0WU
UACC-257	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmnLTWM2OD1zMz61NVI3KM7:TR?=	MWjTRW5ITVJ?
Calu-6	NUL6NoRRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4DlOWlEPTB;MUOuOlA1PiEQvF2=	Mk\FV2FPT0WU
NCI-H1882	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M13zNmlEPTB;MUOuPFU2PSEQvF2=	MUHTRW5ITVJ?
BB30-HNC	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV75bnNuUUN3ME2xOE4xPjB7IN88US=>	NH3nfZJUSU6JRWK=
ES1	M{frd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX\JR\|UxRTF2LkG1OVEh\|ryP	MUXTRW5ITVJ?
NCI-H1694	M1vpeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnvoTWM2OD1zND60PFEyKM7:TR?=	NUjFe3R[W0GQR1XS
IST-SL1	NVvkfG5xT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVmzd3BJUUN3ME2xOE46PjF4IN88US=>	MVXTRW5ITVJ?
ECC4	M3f1eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUnJR\|UxRTF3LkC1OVgh\|ryP	NEjo[GFUSU6JRWK=
MDA-MB-134-VI	NEnocmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NELUTWRKSzVyPUG1MlQyOzFizszN	MUjTRW5ITVJ?
SCH	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mlq5TWM2OD1zNT60O\|I5KM7:TR?=	MmXTV2FPT0WU
SK-N-FI	NULlcVNjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVrlOJlZUUN3ME2xOU43PTN2IN88US=>	M4\qcnNCVkeHUh?=
HDLM-2	NXz1RlhKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVTJR\|UxRTF4LkC3NVQh\|ryP	M3fpVHNCVkeHUh?=
Ramos-2G6-4C10	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3;ySGlEPTB;MU[uNVI6PyEQvF2=	NVjEW\|Z4W0GQR1XS
EW-24	NV;3UVZMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYPTfnF1UUN3ME2xOk4yPjZzIN88US=>	NIP4S2NUSU6JRWK=
NCI-H2141	NHW0S5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnvTTWM2OD1zNj6xPFkh\|ryP	NFPlepFUSU6JRWK=
LC4-1	M4q2c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVrJR\|UxRTF4Lk[xNVkh\|ryP	M2rTdHNCVkeHUh?=
HT-144	NXTxNlhPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVnJR\|UxRTF5LkCwOkDPxE1?	NHfpXYdUSU6JRWK=
SK-MEL-1	M3rKd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX;SdldNUUN3ME2xO{4xODd{IN88US=>	NHG0UFZUSU6JRWK=
SCC-15	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{HOeWlEPTB;MUeuNVY{QCEQvF2=	NGfhfoVUSU6JRWK=
C8166	M1X4PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEfJb5VKSzVyPUG3MlY5OzNizszN	M3fNTnNCVkeHUh?=
GOTO	M2D4fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX\JR\|UxRTF5LkizOFQh\|ryP	Mk\GV2FPT0WU
COR-L279	NHG2OXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlnjTWM2OD1zOD6xN\|YzKM7:TR?=	NEfFOWNUSU6JRWK=
K-562	MlXyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXjJR\|UxRTF6LkexOFMh\|ryP	MnfVV2FPT0WU
ES3	NEfMfWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFL2SJRKSzVyPUG4MlgxPDFizszN	MUfTRW5ITVJ?
LU-165	M2HyOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVHJR3BvUUN3ME2xPU44ODB6IN88US=>	NX7Rcpd7W0GQR1XS
KM-H2	M2DEeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NETzOGJKSzVyPUKwMlMyQDRizszN	MlzzV2FPT0WU
RL	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVzJR\|UxRTJyLkm2PVIh\|ryP	Mki3V2FPT0WU
EW-3	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV3tXW5UUUN3ME2yNU4yQDh7IN88US=>	NYXvXoNuW0GQR1XS
A101D	NYTBV405T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUXJR\|UxRTJzLkO3OVIh\|ryP	MUXTRW5ITVJ?
HUTU-80	MnHFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkjlTWM2OD1{MT6zPVQ3KM7:TR?=	MWXTRW5ITVJ?
NCI-H23	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFzSXplKSzVyPUKxMlM6QTJizszN	NYLabXc6W0GQR1XS
PF-382	NYfpNWhYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEjHW\|BKSzVyPUKxMlQ1ODNizszN	M{DGVHNCVkeHUh?=
LB373-MEL-D	NHT5eoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEjEdphKSzVyPUKxMlU3OTVizszN	MmnRV2FPT0WU
TE-8	NVKwXGppT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHz4O5pKSzVyPUKxMlY{QTRizszN	MXHTRW5ITVJ?
TE-9	NUjVbYZtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2HSdWlEPTB;MkGuPFUyOyEQvF2=	NEH6UlNUSU6JRWK=
Daudi	NUL3PXNPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVTxe3d5UUN3ME2yNU46OzB2IN88US=>	MljuV2FPT0WU
D-542MG	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmHGTWM2OD1{Mj6wNlU3KM7:TR?=	M{jHbXNCVkeHUh?=
U-698-M	Ml3TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIfVZW5KSzVyPUKyMlQ3ODNizszN	MkfmV2FPT0WU
ES6	M4n0VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkS5TWM2OD1{Mj63N\|Y3KM7:TR?=	Mmr0V2FPT0WU
DU-4475	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWjJR\|UxRTJ\|Lki4PVch\|ryP	MnO4V2FPT0WU
ECC12	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlHmTWM2OD1{ND6yPFA{KM7:TR?=	MWHTRW5ITVJ?
C2BBe1	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVrJR\|UxRTJ2LkOyN\|kh\|ryP	MnfTV2FPT0WU
IST-SL2	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEXVcItKSzVyPUK0MlQ{PjJizszN	NVzHVGd3W0GQR1XS
DJM-1	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGe2NotKSzVyPUK0MlUzOjFizszN	NFHWW2RUSU6JRWK=
DMS-153	NULJfVlET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVLJR\|UxRTJ2Lki2NVQh\|ryP	Ml7mV2FPT0WU
NB13	NInjVGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUXaZlgyUUN3ME2yOU4xOjZ3IN88US=>	NFvXRW5USU6JRWK=
SK-N-DZ	NHjrb5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEjEWWhKSzVyPUK2MlM1OTRizszN	MoPuV2FPT0WU
COR-L88	NITFOXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3v1fmlEPTB;Mk[uOVc6PiEQvF2=	NGXlcHZUSU6JRWK=
LU-65	NXv2OYhWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWXJR\|UxRTJ4Lki1N\|Uh\|ryP	M3r6OXNCVkeHUh?=
TGBC1TKB	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1n1e2lEPTB;Mk[uPVgzQCEQvF2=	MUTTRW5ITVJ?
THP-1	NGrpNVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYTkR3ZlUUN3ME2yO{4zOTRzIN88US=>	NUO0O5hmW0GQR1XS
ONS-76	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M13TUmlEPTB;MkeuN\|MzKM7:TR?=	M1rmRXNCVkeHUh?=
LC-2-ad	NETwRoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYDJR\|UxRTJ5Lk[yN\|Eh\|ryP	MXPTRW5ITVJ?
EW-13	NY\4OJBDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGTkcoJKSzVyPUK5MlE4PDZizszN	NF;lUotUSU6JRWK=
MS-1	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXjsc4ZnUUN3ME2zNE44Ojd6IN88US=>	MXrTRW5ITVJ?
NCI-H2227	NGjrdVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4fHZ2lEPTB;M{CuPVgxPiEQvF2=	NGizRWdUSU6JRWK=
LXF-289	M1y5bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYjJR\|UxRTNzLkS0PVIh\|ryP	MmfnV2FPT0WU
MC116	NVvPd4NwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NW\Sd4FtUUN3ME2zNk4xQDJ4IN88US=>	Mnn1V2FPT0WU
EVSA-T	MmPSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVPTVnZiUUN3ME2zNk4zPTh3IN88US=>	MWfTRW5ITVJ?
CTB-1	Ml\pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NG\ZU3dKSzVyPUOzMlEyODFizszN	MYjTRW5ITVJ?
COLO-320-HSR	NVvLcXA1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWDJR\|UxRTN\|LkG2NFMh\|ryP	NIHUdXNUSU6JRWK=
NCI-H2196	NVnKSHZuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHLQTZRKSzVyPUOzMlI2PTdizszN	M2KzVXNCVkeHUh?=
LB2241-RCC	NYPMTnNLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlrqTWM2OD1\|Mz6zNVM2KM7:TR?=	NXK0SJF4W0GQR1XS
LS-513	MnfVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF\L[XdKSzVyPUOzMlg3OzhizszN	NWj3SYE6W0GQR1XS
LP-1	NGW4d2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{XwNWlEPTB;M{OuPVk2PiEQvF2=	M{DyfHNCVkeHUh?=
A253	NXHLV2JPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF3TZm9KSzVyPUO0MlIzQTZizszN	MkD1V2FPT0WU
SK-MM-2	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEPkR3dKSzVyPUO0Mlk1PTFizszN	Ml;OV2FPT0WU
NCI-H1963	NGfOVGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mm\oTWM2OD1\|NT6zNFczKM7:TR?=	MVrTRW5ITVJ?
MMAC-SF	M1;LZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUPjbIFoUUN3ME2zOU45Pzh3IN88US=>	NHXBVYRUSU6JRWK=
LB831-BLC	NX7zNVJLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3P4VWlEPTB;M{[uNFY2PCEQvF2=	NYPpPZNMW0GQR1XS
WSU-NHL	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1j4PWlEPTB;M{[uNVY1KM7:TR?=	NGHxXWNUSU6JRWK=
CESS	NY\WeldIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4HHemlEPTB;M{[uNlg1QCEQvF2=	NIr2TGVUSU6JRWK=
NEC8	MoT6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVrJR\|UxRTN4LkW4N\|Uh\|ryP	NXHXdlhSW0GQR1XS
KNS-42	Mk\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV\JR\|UxRTN5LkGyN\|ch\|ryP	M2Gxe3NCVkeHUh?=
MHH-CALL-2	NF\IV2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3i5PGlEPTB;M{euNVgzOSEQvF2=	M1G5[nNCVkeHUh?=
K5	NFPGUIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF\jfJhKSzVyPUO4MlQ{KM7:TR?=	MoDOV2FPT0WU
CP66-MEL	NFLk[mtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVfJR\|UxRTN7LkC3N\|Mh\|ryP	M4q4NHNCVkeHUh?=
OPM-2	MmTvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnW5TWM2OD1\|OT64OFMzKM7:TR?=	M37uNHNCVkeHUh?=
IST-MES1	M{HBeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4\WdmlEPTB;NECuN\|A6PiEQvF2=	NEX2RodUSU6JRWK=
EC-GI-10	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4nUU2lEPTB;NEGuOVgxPSEQvF2=	MlzUV2FPT0WU
CTV-1	NXjOelNQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXewcGxCUUN3ME20Nk45PDB4IN88US=>	NFjubXlUSU6JRWK=
DG-75	MkewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUHUcJhVUUN3ME20N{44PTl3IN88US=>	NYe4elRjW0GQR1XS
KNS-81-FD	NUe0c5JiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MU\JR\|UxRTR3LkSwOVgh\|ryP	NHLYW2hUSU6JRWK=
NCI-H82	NHPwW3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGHTRVFKSzVyPUS1MlU4PThizszN	Mli1V2FPT0WU
RPMI-8866	MlmzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFPCNI5KSzVyPUS2MlE5PzNizszN	Mn;YV2FPT0WU
ACN	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M325cGlEPTB;NE[uOFM1KM7:TR?=	NWTONXpEW0GQR1XS
NCI-H1395	NX[1bYo6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFTrU5pKSzVyPUS2MlQ4PTZizszN	NX74XnVLW0GQR1XS
NCI-H209	NUOwUpB1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEnK[4VKSzVyPUS3MlE1ODVizszN	Mn30V2FPT0WU
TGW	NUTiZpZ{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NU\tOXR6UUN3ME20PU4xPzlzIN88US=>	MkjhV2FPT0WU
NCI-H748	Ml;1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVTJR\|UxRTR7LkS3OVMh\|ryP	M4nLZXNCVkeHUh?=
EKVX	MnLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M33xOGlEPTB;NEmuOlYzQCEQvF2=	Mkn3V2FPT0WU

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	LC3-I / LC-3II / ATG5; PubMed: 23392173 Cell Death Dis Sorafenib induces the conversion of LC3 in a dose-dependent manner. PLC5, Hep3B, SK-Hep1 and HepG2 were exposed to sorafenib at the indicated doses for 16 h and the expression levels of LC3-II were analyzed by western blot. p-STAT3 / STAT3 / Mcl-1; PubMed: 23392173 Cell Death Dis Effects of sorafenib on STAT3-related proteins in HCC cells. The cells were treated with sorafenib at the indicated dose for 16 h. β-catenin / Survivin / Mcl-1 / PTMA; PubMed: 26517516 Oncotarget Co-inhibition of β-catenin and PTMA by sorafenib in HCC cells. Cell lines indicated on top were treated or not with 10 μM sorafenib for 24 hrs and processed for immuno-blotting. IC50 values (the concentration of sorafenib that inhibits 50% of cell growth) for each cell line are indicated below the panels. pERK / ERK; PubMed: 22286758 Oncogene Western blot analysis of p-ERK (T202/Y204) and ERK at indicated time points in HCT116 cells treated with 20 μmol/L sorafenib. p-PKM2(y105) / PMK2 / Caspase-9; PubMed: 26959741 Oncotarget Sorafenib downregulates the p-PKM2 (Y105) at the indicated doses after treatment for 24 h. RET(pY1016) / VEGFR2(pY1214) / MEK1(pT292) / ERK(pY204); PubMed: 22941289 Acta Pharmacol Sin Sorafenib affected the phosphorylation of receptor tyrosine kinase RET and VEGFR2, as well as MEK/ERK kinases signaling cascades in three cell lines. Three cell lines were treated by sorafenib with two concentration gradients, 1 and 5 μmol/L/L, and then collected after 2, 4, and 8 h, cells without sorafenib treatment were as the controls (0 h). Total proteins were extracted and quantified to be used in Western blot assays. (A) Sorafenib inhibited RET and VEGFR2 phosphorylation dose-dependently while activated MEK and ERK phosphorylation in A549 cells. (B) Sorafenib also inhibited RET and VEGFR2 phosphorylation, and slightly activated MEK and ERK phosphorylation in HeLa cells. (C) Sorafenib activated the phosphorylation of RET, VEGFR2, and MEK, but inhibited ERK phosphorylation in HepG2 cells. Cyclin D1; PubMed: 26039995 Proc Natl Acad Sci U S A Dose-escalation effects of sorafenib or SC-1 for 24 h on STAT3-related proteins in HSC-T6 and LX2 cells.	23392173 26517516 22286758 26959741 22941289 26039995
Growth inhibition assay	Cell viability; PubMed: 26039995 Proc Natl Acad Sci U S A Dose-escalation and time-dependent effects of sorafenib for 24 or 48 h on cell viability in HSC-T6, LX2, and mouse primary HSCs. Circles, mean; bars, SE (n = 3).	26039995
Immunofluorescence	p65; PubMed: 22286758 Oncogene HCT116 cells were treated with 20 μmol/L sorafenib or 10 ng/mL TNF-α for 3 hours then fixed. Immunofluorescence was carried out as described in the Materials and Methods for p65 (green) and DAPI (blue). Representative pictures (400×) are shown. cytochrome c; PubMed: 22278289 Cell Death Dis Immunoflourescent staining and quantification of mitochondrial membrane potential (appearing in red, mitotracker) and cytochrome c (appearing in green, FITC) in 22Rv1 and PC3 treated with 20 μM sorafenib for 24 h.	22286758 22278289
ELISA	TGF-beta / CD206; PubMed: 26158762 Oncotarget In Macrophage, TGF-β secretion and CD206 were confirmed by ELISA. Caspase-9 / Caspase-3; PubMed: 30923462 Cancer Cell Int Caspase-9 and caspase-3 activities were measured via ELISA assay. FCCP, an activator of mitophagy, was added into the medium of sorafenib-treated cells to activate mitophagy. Adenovirus-loaded LATS2 (Ad-LATS2) was transfected into HepG2 cells in the presence of sorafenib. *p < 0.05 vs. control group; #p < 0.05 vs. Sorafenib + Ad-cont group; #p < 0.05 vs. Sorafenib + Ad-LATS2 group.	26158762 30923462

体内研究

Sorafenib(~60 mg/kg)口服给药，对各种人肿瘤异种移植模型，包括MDA-MB-231，Colo-205，HT-29，DLD-1，NCI-H460，和A549表现出广谱的、剂量依赖性抗肿瘤活性，而没有毒性。与抗肿瘤功效相联系，Sorafenib 治疗有效抑制HT-29 和 MDA-MB-231异种移植物中MEK 1/2磷酸化和pERK 1/2水平，但对Colo-205异种移植物没有作用，并且也能显著抑制MDA MB-231，HT-29 和 Colo-205肿瘤异种移植物中肿瘤微血管面积(MVA)和微血管密度(MVD)。^[1] 在SCID小鼠体内，Sorafenib治疗对PLC/PRF/5肿瘤异种移植产生剂量依赖性生长抑制，10 mg/kg和30 mg/kg剂量下，TGIs分别为49%和78%，与ERK 和 eIF4E磷酸化抑制，微血管面积减少，和肿瘤细胞凋亡的诱导相一致。^[2] Sorafenib通过下调NF-κB介导的Mcl-1 和 cIAP2表达的作用机制使bax^-/-细胞对TRAIL剂量依赖性敏感。 Sorafenib (30-60 mg/kg) 与 TRAIL (5 mg/kg)结合对TRAIL抗性HCT116 bax^-/-和HT29肿瘤异种移植物表现出显著的功效。^[3]

激酶实验：^[1]	- 合并生化检测: 重组杆状病毒表达的Raf-1 (残基305–648)和 B-Raf (残基 409–765)以融合蛋白纯化。全长人MEK-1由PCR产生，并以大肠杆菌裂解物中的融合蛋白纯化。将Sorafenib加入到含Raf-1 (80纳克)，或B-Raf (80 纳克) 以及MEK-1 (1 微克) 混合物的实验缓冲液[20 mM Tris (pH 8.2)，100 mM NaCl，5 mM MgCl₂，和0.15% β-巯基乙醇]中，DMSO终浓度为1%。加入25微升10 μM γ[³³P]ATP (400 Ci/mol)启动Raf激酶试验(终体积50微升)，并在32 °C下培育25分钟。磷酸化的MEK-1通过过滤到磷酸纤维素板上采集，使用1%磷酸洗掉未结合的放射性。微波炉加热干燥后，使用β型板计数器量化过滤器结合放射性。人VEGFR2 (KDR)激酶域被表达，并从Sf9裂解物中纯化。VEGFR2的时间分辨荧光分析法能量转移测试在96孔不透明板中以时间分辨荧光分析法能量转移格式进行。最终反应条件如下：1 到10 μM ATP，25 nM poly GT生物素，2 nM 铕标记的磷酸(p)-酪氨酸抗体(PY20)，10 nM APC，1% DMSO 终浓度的1 到 7 nM 细胞质激酶域，50 mM HEPES (pH 7.5)，10 mM MgCl₂，0.1 mM EDTA，0.015% Brij-35，0.1 毫克/毫升BSA，和0.1% β-巯基乙醇。反应体积为100微升，加入酶启动反应。反应启动~1.5 到 2.0小时后，板以615 和 665 nM在Perkin-Elmer VictorV多标记分析仪上读数。信号按如下比率计算：对每孔(665 nm/615 nM) × 10,000。对IC50的产生，在酶起始反应之前加入Sorafenib。50倍的库存板由Sorafenib在50% DMSO/50%蒸馏水溶液中连续稀释制得。最终Sorafenib在1% DMSO中的浓度范围为10 μM 到 4.56 nM。
细胞实验：^[1]	- 合并 Cell lines: MDA-MB-231，和 HAoSMC Concentrations: 溶解于DMSO，终浓度为~10 μM Incubation Time: 72小时 Method: 细胞在逐渐增加浓度的Sorafenib下暴露72小时。细胞数通过Cell TiterGlo ATP发光测定试剂盒进行定量。该试验通过测定基于细胞中ATP量的发光信号，测量每孔中的活细胞。 (Only for Reference)
动物实验：^[1]	- 合并 Animal Models: 雌性 NCr-nu/nu 小鼠，皮下植入MDA-MB-231，Colo-205，HT-29，H460，或 A549 细胞 Formulation: 以4倍(4 ×储备溶液，稀释为1 ×)溶解于聚氧乙烯蓖麻油/乙醇(50:50) Dosages: ~60 mg/kg Administration: 口服，每天一次 (Only for Reference)

参考文献

溶解度 (25°C)

体外	DMSO	63 mg/mL warmed (135.53 mM)
	Water	Insoluble
	Ethanol	Insoluble
体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： 5% DMSO+45% PEG 400+ddH2O	3mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download Sorafenib SDF

分子量	464.82
化学式	C₂₁H₁₆ClF₃N₄O₃
CAS号	284461-73-0
储存条件	3年 -20°C粉状
储存条件	2年 -80°C 溶于溶剂
别名	BAY 43-9006

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

临床试验信息 (data from https://clinicaltrials.gov, updated on 2019-10-14)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04000737	Not yet recruiting	Drug: YIV-906+Sorafenib\|Drug: Placebo+Sorafenib	Advanced Hepatocellular Carcinoma	Yiviva Inc.	August 15 2019	Phase 2
NCT03958669	Not yet recruiting	--	Hepatocellular Carcinoma\|Sorafenib	University Hospital Tuebingen\|German Federal Ministry of Education and Research	July 1 2019	--
NCT03764293	Not yet recruiting	Drug: SHR-1210\|Drug: Apatinib\|Drug: Sorafenib	Locally Advanced or Metastatic and Unresectable HCC	Jiangsu HengRui Medicine Co. Ltd.	January 2019	Phase 3
NCT03582618	Recruiting	Drug: Sorafenib\|Drug: CVM-1118	Hepatocellular Carcinoma\|Advanced Cancer	TaiRx Inc.	July 12 2018	Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

研究领域

产品类型

Sorafenib

客户使用Selleck生产的Sorafenib发表文献206篇：

产品安全说明书

Raf抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download Sorafenib SDF

计算器

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

临床试验信息 (data from https://clinicaltrials.gov, updated on 2019-10-14)

技术支持

Raf Signaling Pathway Map

相关Raf产品